A study to investigate the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants.

Trial Identifier: D6830C00002
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: October 2024
Study Completion Date: October 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Master Version

Trial Locations

Country Location
US, MD Baltimore, MD, US, 21225